BioXcel Therapeutics, Inc.
BTAIQ Healthcare Drug Manufacturers Specialty & Generic
BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024. In the quarter to June 2026, revenue grew 51.7%, EPS grew 80.0%, free cash flow grew 51.5% and total debt fell 3.90%, each against the same quarter a year earlier.
Follow BTAIQ
BioXcel Therapeutics, Inc. (BTAIQ) P/E ratio
BioXcel Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMCC IM Cannabis Corp. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. | n/m |
| PTPI Petros Pharmaceuticals, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| NEPTF Neptune Wellness Solutions Inc. compare | n/m |
| YCBD cbdMD, Inc. compare | 41.2× |
| GELS Gelteq Limited compare | — |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)